4/16
09:12 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $205.00 price target on the stock.
Medium
Report
Ascendis Pharma A/S (NASDAQ: ASND) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $205.00 price target on the stock.
3/31
04:01 pm
asnd
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
Low
Report
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
3/27
05:31 pm
asnd
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight
Low
Report
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight
3/27
05:31 pm
asnd
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight
Low
Report
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight
3/18
08:37 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $168.00 to $200.00. They now have an "overweight" rating on the stock.
Medium
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $168.00 to $200.00. They now have an "overweight" rating on the stock.
2/26
03:00 am
asnd
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director
Low
Report
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director
2/25
09:31 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Cantor Fitzgerald from $170.00 to $200.00. They now have an "overweight" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Cantor Fitzgerald from $170.00 to $200.00. They now have an "overweight" rating on the stock.
2/24
04:01 pm
asnd
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Low
Report
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
2/22
03:30 pm
asnd
Ascendis Pharma A/S (NASDAQ: ASND) was given a new $180.00 price target on by analysts at Morgan Stanley.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) was given a new $180.00 price target on by analysts at Morgan Stanley.
2/20
11:44 am
asnd
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA [Yahoo! Finance]
Low
Report
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA [Yahoo! Finance]
2/20
11:01 am
asnd
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
Low
Report
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
2/18
10:43 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Evercore ISI from $220.00 to $260.00. They now have an "outperform" rating on the stock.
Medium
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Evercore ISI from $220.00 to $260.00. They now have an "outperform" rating on the stock.
2/16
07:15 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
2/14
06:55 am
asnd
Ascendis Pharma Full Year 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Ascendis Pharma Full Year 2024 Earnings: Beats Expectations [Yahoo! Finance]
2/13
03:15 pm
asnd
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? [Yahoo! Finance]
Low
Report
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? [Yahoo! Finance]
2/13
12:40 pm
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $200.00 to $225.00. They now have a "buy" rating on the stock.
Medium
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $200.00 to $225.00. They now have a "buy" rating on the stock.
2/13
10:58 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $167.00 to $168.00. They now have an "overweight" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $167.00 to $168.00. They now have an "overweight" rating on the stock.
2/12
11:05 pm
asnd
Ascendis Pharma targets €200M SKYTROFA revenue and expands YORVIPATH globally in 2025 [Seeking Alpha]
Low
Report
Ascendis Pharma targets €200M SKYTROFA revenue and expands YORVIPATH globally in 2025 [Seeking Alpha]
2/12
05:57 pm
asnd
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs [Yahoo! Finance]
Medium
Report
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs [Yahoo! Finance]
2/12
05:57 pm
asnd
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Medium
Report
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/12
04:05 pm
asnd
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
Medium
Report
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
2/12
04:01 pm
asnd
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
High
Report
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
2/11
10:32 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
2/5
04:50 pm
asnd
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 [Yahoo! Finance]
Medium
Report
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 [Yahoo! Finance]
2/5
04:01 pm
asnd
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025
Medium
Report
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025